Clinical trials with afatinib, pyrotinib, trastuzumab emtansine, and trastuzumab deruxtecan are being evaluated for their efficacy against EGFR‐TKI‐resistant ERBB2 amplified lung cancers.39 This evidence concerns the gene ERBB2 and lung carcinoma.